Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The prognostic value of biomarker levels and chest imaging in patients with COVID-19 presenting to the emergency department

Gilbert Abou Dagher, MD MBA a, Alain Abi Ghanem, MD b, Saadeddine Haidar, MD a, Nadim Kattouf, MD a, Mohamad Assaf, MD c, Mihran Khdir, MD b, Reve Chahine, MD b, Jennifer Rizk, MD a, Maha Makki, MSc c, Hani Tamim, PhD c, Ralph Bou Chebl, MD a,⁎

a Department of Emergency Medicine, American University of Beirut, Beirut, Lebanon
b Department of Radiology, American University of Beirut, Beirut, Lebanon
c Department of Internal Medicine, American University of Beirut, Beirut, Lebanon

A R T I C L E   I N F O

Article history:
Received 5 April 2022
Received in revised form 29 May 2022
Accepted 18 June 2022

Keywords:
COVID-19
Mortality
Chest CT
Biomarkers
Neutrophil to lymphocyte ratio
C-reactive protein

A B S T R A C T

Introduction: We aimed to compare the prognostic value of a quantitative CT severity score with several laboratory parameters, particularly C-reactive protein, Procalcitonin, Neutrophil to lymphocyte ratio, D-dimer, ferritin, lactate dehydrogenase, lactate, troponin and B-type Natriuretic Peptide in predicting in-hospital mortality.

Methods: This was a retrospective chart review study of COVID-19 patients who presented to the Emergency Department of a tertiary care center between February and December 2020. All patients ≥18 years old who tested positive for the COVID-19 real-time reverse transcriptase polymerase chain reaction and underwent CT imaging at presentation were included. The primary outcome was the prognostic ability of CT severity score versus biomarkers in predicting in-hospital mortality.

Results: The AUCs were: D-dimer (AUC: 0.67 95% CI = 0.57–0.77), CT severity score (0.66, 95% CI = 0.55–0.77), LDH (0.66, 95% CI = 0.55–0.77), Pro-BNP (0.65, 95% CI = 0.55–0.76), NLR (0.64, 95% CI = 0.53–0.75) and troponin (0.64, 95% CI = 0.52–0.75). In the stepwise logistic regression, age (OR = 1.07 95% CI = 1.05–1.09), obesity (OR = 2.02 95% CI = 1.25–3.26), neutrophil/lymphocyte ratio (OR = 1.02 95% CI = 1.01–1.04), CRP (OR = 1.01 95% CI = 1.00–1.00) and CT severity score (OR = 1.17 95% CI = 1.12–1.23) were significantly associated with in-hospital mortality.

Conclusion: In summary, CT severity score outperformed several biomarkers as a prognostic tool for covid related mortality. In COVID-19 patients requiring lung imaging, such as patients requiring ICU admission, patients with abnormal vital signs and those requiring mechanical ventilation, the results suggest obtaining and calculating the CT severity score to use it as a prognostic tool. If a CT was not performed, the results suggest using LDH, CRP or NLR if already done as prognostic tools in COVID-19 as these biomarkers were also found to be prognostic in COVID-19 patients.

© 2022 Published by Elsevier Inc.
patients (5). Laboratory parameters such as neutrophil to lymphocyte ratio (NLR), procalcitonin (PCT), C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase (LDH), lactate, troponin and B-type Natriuretic Peptide (Pro-BNP) have been studied in COVID-19 patients (6-14). They have been shown to be associated with disease severity, mortality and hospital complications (ARDS, need for invasive and noninvasive mechanical ventilation, venous thromboembolism and acute kidney injury) (6-14). Similarly, the prognostic utility of chest computed tomography (CT) has been studied in COVID-19 patients. In April 2020, a multinational committee advised that chest CT is a more sensitive imaging modality than chest x-ray (CXR) for early detection of and assessment of COVID-19 disease severity (15). Ground glass opacities or bilateral consolidations in the lower lung field are the most common CT features among COVID-19 patients (16,17). Studies have reported scoring systems, findings and quantitative analyses of CT images that correlate with disease severity and predict outcomes of COVID-19 (16-21).

1.2. Importance

This study may help identify tools that can be used to risk stratify patients presenting to the emergency department with Covid-19 and guide patient management.

1.3. Goal of the investigation

In this study, we aimed to compare the prognostic value of a quantitative CT severity score with several laboratory parameters, particularly C-reactive protein (CRP), Procalcitonin (PCT), Neutrophil to lymphocyte ratio (NLR), D-dimer, ferritin, lactate dehydrogenase (LDH), lactate, troponin and B-type Natriuretic Peptide (Pro-BNP) in predicting in-hospital mortality.

2. Methods

2.1. Study design and setting

This was a retrospective chart review study of patients who presented to the Emergency Department (ED) of a tertiary care center between February 2020 and December 22, 2020 and were diagnosed with COVID-19.

2.2. Selection of participants

All patients ≥18 years old who tested positive for the COVID-19 real-time reverse transcriptase polymerase chain reaction (RT-PCR) and underwent CT imaging at presentation were included. Patients below 18 years old, pregnant women, trauma patients and cardiac arrest patients were excluded. Patients who did not undergo Computer tomography (CT) chest imaging were also excluded. The included patients were divided into 2 groups: survivors and non-survivors. This study was conducted during a time where the COVID-19 vaccine was not available. It was approved by the hospital’s Institutional Review Board (IRB): BIO-2020-0548.

2.3. Data abstraction

Three research fellows were responsible for data abstraction. They completed training for data abstraction before the start of the study using practice medical records as well as having several meeting with the principal investigator for quality control. A list of patients with both a positive COVID-19 PCR and a chest CT was obtained from the hospital electronic health record system (EPIC©). The research fellows screened the obtained list based on the inclusion and exclusion criteria by reviewing their medical charts. Relevant patient characteristics, vital signs, and lab parameters at baseline, in addition to diagnostic and therapeutic interventions and outcomes of the included patients were extracted from the hospital electronic health record system (EPIC©). Standardized abstraction forms were used during data collection (Research Electronic Data Capture- Redcap). The performance of the data abstractors was monitored frequently by the principal investigators of the study and the department’s research coordinator. The data abstractors were not blinded to the hypothesis and objectives of the study because they were involved in the writing of the manuscript. In addition, each medical chart was reviewed by a single research fellow for data abstraction.

2.4. Variables and definitions

The variables of interest that were extracted were: age, gender, height, weight, body mass index (BMI), medical comorbidities, smoking status, vital signs, patients’ presenting symptoms, complete blood count, electrolytes, biomarkers (lactate, albumin, C-reactive protein, procalcitonin, ferritin, lactate dehydrogenase, D-dimer, Bilirubin, pro-BNP, cardiac troponin), coagulation studies (PT, PTT, INR), liver enzymes (AST, ALT, Alkaline phosphatase, Gamma-glutamyl transferase). CT severity score was calculated for all included patients. Other variables of interest were: ED disposition (discharged, regular hospital floor admission or ICU admission), therapeutic interventions in the ED and during hospital admission (the need for noninvasive or invasive ventilation, hospital and ICU lengths of stay, the presence of pulmonary bacterial co-infection, development of complications such as sepsis, acute respiratory distress syndrome (ARDS), cardiovascular complications, thromboembolic events and death). The Berlin definition of ARDS was used to diagnose patients with ARDS (22). Sepsis was defined based on the Sepsis-3 criteria (23). A patient was considered to have a pulmonary bacterial co-infection if the infectious disease team treated them with antibiotics based on clinical, radiographic and laboratory findings.

2.5. CT severity score

The CT images of COVID-19 patients were reviewed at presentation by board certified radiologists at our institution. The radiologists responsible for reviewing the CT images were blinded to the clinical and laboratory data of the patients. The findings were reported according to the “Radiological Society of North America Expert Consensus Document on Reporting Chest CT Findings Related to COVID-19” (24).

The semi-quantitative CT scoring system used was the same as the one used by Pan et al., whereby the degree of each lung lobe involvement translates to a raw score of 0–5. 0 = no involvement; 1 < 5% involvement; 2 = 25% involvement; 3 = 25–49% involvement; 4 = 50–75% involvement; 5= ≥75% involvement (25). Thus, the total CT score was the sum of the individual lobar scores i.e. a total score of 0 means no lung involvement, and a 25 indicates maximum lung involvement (25). Examples of CT chest images with their corresponding COVID-19 lung involvement and CT severity scores are provided in Fig. 1.

2.6. Outcome of interest

The primary outcome was the prognostic ability of CT severity score versus biomarkers in predicting in-hospital mortality.

2.7. Statistical analysis

In the univariate analysis, continuous variables were presented in the form of mean ± standard deviation, and categorical variables were presented as frequency with percentage. In the bivariate analysis, Student’s t-test and Pearson’s Chi-square test were used to assess the significance of the statistical association between the independent variables in the different groups.

In the multivariate analysis, logistic regression was used to assess the association between biomarkers and CT severity score with
The following variables were included in the logistic regression: Age, gender, BMI, smoking, obesity, Hypertension, Dyslipidemia, Atrial fibrillation, Coronary Artery Disease, Congestive Heart Failure, Malignancy, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, Neutrophil/lymphocyte ratio, Troponin, CRP, Procalcitonin, Lactate dehydrogenase, Ferritin, D-dimer, IL-6, Pro-BNP, CT severity score.

Receiver operating characteristic (ROC) curves were plotted (with regards to mortality) to calculate the area under the curve (AUC) for the relevant biomarkers and CT severity score. Multiple imputations for missing data were not performed because the percentage of missing values for all included variables was <5%. All tests were assessed for significance using 95% CI (Confidence Intervals) and alpha of 0.05. All statistical analyses were performed using SPSS 24 (Statistical Package for Social Sciences).

3. Results

3.1. Baseline characteristics of presenting patients

During the study period a total of 1043 COVID-19 patients were identified, of whom 761 met the inclusion criteria and 282 were excluded (220 with no CT scan of the chest; 30 were pregnant; 32 were below the age of 18) (Fig. 2). 119 patients (15.6%) died during their hospital stay (Table 1).

The mean age of the study population was 60.81 ± 16.93 years, of whom 68.1% (N = 518) were male. The average BMI of the sample population was 28.90 ± 5.21. 21.7% of the total patient population were current smokers. The four most prevalent comorbidities were hypertension (47.7%), dyslipidemia (37.2%), obesity (30.7%) and diabetes mellitus (27.3%). (Table 1). Non-survivors were older (72.94 ± 12.07 years vs. 58.56 ± 16.76 years, p < 0.0005) and had a higher percentage of hypertension (67.2% vs. 44.1%, p < 0.005), atrial fibrillation (15.1% vs. 6.1%, p = 0.001), coronary artery disease (30.3% vs. 15.7%, p < 0.005), malignancy (24.4% vs. 12.8%, p = 0.001) and diabetes mellitus (38.7% vs. 25.2%, p = 0.003), (Table 1).

3.2. Initial vital signs, presenting symptoms and lab parameters

Non-survivors had higher respiratory rates (22 breaths/min ± 5.79 vs 20 ± 3.29 breaths/min, p < 0.0005) and lower oxygen saturation (95% ± 6.71 vs 86% ± 12.03, p < 0.0005) than survivors at presentation.
Table 1: Baseline Characteristics of the COVID-19 patients presenting to the Emergency Department of a tertiary care center.

| Total | Survivors | Non survivors | P-value |
|-------|-----------|---------------|---------|
| N = 761 | N = 642 | N = 119 | |
| Mean ± SD | Mean ± SD | Mean ± SD | |
| N (%) | N (%) | N (%) | |
| Age (years) | 60.81 ± 16.93 | 58.56 ± 16.76 | 72.94 ± 12.07 | <0.0005 |
| Male | 518 (68.1) | 439 (68.4) | 79 (66.4) | 0.67 |
| Height (m) | 1.69 ± 0.10 | 1.69 ± 0.10 | 1.68 ± 0.10 | 0.26 |
| Weight (kg) | 82.35 ± 17.71 | 82.27 ± 17.60 | 83.02 ± 18.15 | 0.67 |
| BMI | 28.90 ± 5.21 | 28.81 ± 5.06 | 29.33 ± 5.80 | 0.34 |
| Obesity | 234 (30.7) | 188 (29.3%) | 46 (38.7) | |
| Smoking | | | | |
| Current | 165 (21.7) | 150 (23.4) | 15 (12.6) | <0.0005 |
| Previous | 122 (16) | 88 (13.7) | 34 (28.6) | |
| None | 474 (62.3) | 404 (62.9) | 70 (58.8) | |
| Chronic kidney disease | 56 (7.4) | 41 (6.4) | 15 (12.6) | 0.017 |
| End stage renal disease | 5 (0.7) | 4 (0.6) | 1 (0.8) | 0.57 |
| Hypertension | 363 (47.7) | 283 (44.1) | 80 (67.2) | <0.0005 |
| Dyslipidemia | 283 (37.2) | 227 (35.4) | 56 (47.1) | 0.015 |
| Atrial fibrillation | 57 (7.5) | 39 (6.1) | 18 (15.1) | 0.001 |
| Coronary Artery Disease | 137 (18.0) | 101 (15.7) | 36 (30.3) | <0.0005 |
| Congestive Heart Failure | 38 (5.0) | 26 (4.0) | 12 (10.1) | 0.006 |
| Malignancy | 111 (14.6) | 82 (12.8) | 29 (24.4) | 0.001 |
| History of thrombo-embolic disease | 60 (7.9) | 45 (7.0) | 15 (12.6) | 0.037 |
| Diabetes Mellitus | 208 (27.3) | 162 (25.2) | 46 (38.7) | 0.003 |
| Chronic Obstructive Pulmonary Disease | 48 (6.3) | 35 (5.5) | 13 (10.9) | 0.024 |

With regards to laboratory parameters, non-survivors had higher WBC counts (9968 cu.mm ± 8491 vs. 7157 cu.mm ± 4758, p = 0.001), neutrophil to lymphocyte ratio (18.92 ± 22.65 vs. 8.5 ± 10.05, p < 0.0005), creatinine (1.3 mg/dL ± 1.24 vs. 1.06 mg/dL ± 0.73, p = 0.04), lactate (2.3 mmol/L ± 1.41 vs. 1.89 mmol/L ± 1.56, p = 0.03), CRP (143 mg/L ± 96 vs. 80 mg/L ± 77.75, p < 0.0005), procalcitonin (1.18 ng/mL ± 3.02 vs. 0.48 ng/mL ± 2.54, p = 0.02), D-dimer (1363 ng/mL ± 2856.94 vs. 730 ng/mL ± 1122.68, p = 0.03) and Pro-BNP (5822 ng/L ± 6836.06 vs. 1470 ng/L ± 3398.87, p = 0.02). Finally, non-survivors had a higher semi-quantitative CT severity score (16.02 ± 5.89 vs. 10.84 ± 6.11, p < 0.0005), LDH (0.66, 95% CI = 0.54–0.77, p = 0.007), Pro-BNP (0.65, 95% CI = 0.55–0.76, p = 0.009), NLR (0.64, 95% CI = 0.53–0.75 p = 0.02) (Fig. 3).

3.3. Oxygen therapy requirements

The percentages of patients who received non-invasive ventilation during the first 24 and 48 h of hospitalization were significantly higher in the non-survivor group (79% vs. 33.2% within the first 24 h and 73.1% vs. 32.4% within 24–48 h p < 0.0005). Moreover, the percentages of patients requiring intubation within the first 24 or 24–48 h of hospitalization were significantly higher in the non-survivor group (10.9% vs. 1.7% within 24 h and 16.8% vs. 0.9% within 24–48 h, both p < 0.0005). A higher percentage of the non-survivors received mechanical ventilation during their hospital stay (Table 3).

3.4. Outcomes of COVID-19 patients

During their hospital stay, 14.5% of patients were directly admitted to the ICU from the ED, 13.5% developed septic shock and 12.2% developed ARDS (Table 4).

Non-survivors had a significantly higher rate of ICU admission (52.9% vs 7.3%), septic shock (69.7% vs 3.1%) and ARDS (62.2% vs 3%) than survivors (Table 4). Non-survivors also had a significantly higher hospital length of stay and ICU length of stay: (130.39 ± 123.21 days vs 26.64 ± 51.23 days and 20.25 ± 4.57 days vs 10.45 ± 9.25 days respectively) (Table 4).

3.5. ROC curves and AUCs with regards to mortality

The variables that had the highest AUCs were: D-dimer (AUC: 0.67 95% CI = 0.57–0.77, p = 0.003), CT severity score (0.66, 95% CI = 0.55–0.77 p = 0.005), LDH (0.66, 95% CI = 0.54–0.77, p = 0.007), Pro-BNP (0.65, 95% CI = 0.55–0.76, p = 0.009), NLR (0.64, 95% CI = 0.53–0.75 p = 0.02) (Fig. 3).

3.6. Multivariate logistic regression analysis for in-hospital mortality

In the stepwise logistic regression, age (OR = 1.07 95% CI = 1.05–1.09, p < 0.0001), obesity (OR = 2.02 95% CI = 1.25–3.26, p = 0.004), neutrophil/lymphocyte ratio (OR = 1.02 95% CI = 1.01–1.04, p = 0.003), CRP (OR = 1.01 95% CI = 1.004–1.009, p < 0.0001), lactate dehydrogenase (OR = 1.003 95% CI = 1.001–1.004, p < 0.0001) and CT severity score (OR = 1.17 95% CI = 1.12–1.23, p < 0.0001) were significantly associated with in-hospital mortality (Table 5).

4. Discussion

In this retrospective chart review, our main aim was to identify and compare the prognostic utility of a semi-quantitative CT severity score with several biomarkers. Out of the total patient population, 119 patients (15.6%) died during their hospital stay. The AUCs for predicting mortality from highest to lowest were CT severity score (0.66), LDH (0.66) and NLR (0.64). The variables that were found to be associated with in-hospital mortality were NLR, CRP, LDH and CT severity score, with the CT severity score outperforming all other biomarkers as a prognostic tool. Our results are in line with the existing literature, where several studies have demonstrated that certain baseline patient characteristics, laboratory parameters and imaging findings are associated with adverse complications in COVID-19.

Age and obesity have been reported to play a major role in predicting mortality and assessing severity of COVID-19 (26-29). Gao et al. and Marin et al. reported that age was an independent predictor of in-hospital mortality (5,9). Moreover, COVID-19 patients above 59 years were 5.1 times more likely to die after developing symptoms (9). According to the Center for Disease control (CDC), a BMI >30 (obesity) increases the risk of severe COVID-19 disease (30). Obesity was also shown to be an independent risk factor associated with hospitalization and death, particularly...
Table 2

Initial vital signs, presenting symptoms and lab parameters of the COVID-19 patients presenting to the Emergency Department of a tertiary care center.

|                          | Total Survivors | Non survivors | P value |
|--------------------------|-----------------|---------------|---------|
|                          | N = 761         | N = 642       | N = 119 |
|                          | Mean ± SD       | Mean ± SD     | Mean ± SD |
|                          | N (%)           | N (%)         | N (%)   |
| Systolic blood pressure (mmHg) | 129.12 ± 18.62 | 129.03 ± 18.53 | 129.60 ± 19.17 | 0.8 |
| Diastolic blood pressure (mmHg) | 73.28 ± 11.8 | 73.29 ± 11.66 | 73.29 ± 12.59 | 0.9 |
| Heart rate (beats/min) | 92.03 ± 17.4 | 91.29 ± 16.93 | 96.95 ± 19.37 | 0.015 |
| O2 saturation (%) | 93 ± 8.34 | 95 ± 6.71 | 86 ± 12.03 | <0.0005 |
| Temperature (°C) | 37.79 ± 0.84 | 37.18 ± 0.83 | 37.25 ± 0.82 | 0.415 |
| Respiratory rate (Breaths/min) | 20 ± 3.89 | 20 ± 3.29 | 22 ± 5.79 | <0.0005 |

Presenting symptoms:

| Presenting symptoms | Total Survivors | Non survivors | P value |
|---------------------|-----------------|---------------|---------|
| Fever               | 483 (63.5)      | 405 (63.1)    | 78 (65.5) | 0.61 |
| Cough               | 432 (56.8)      | 366 (57.0)    | 66 (55.5) | 0.75 |
| Shortness of Breath| 472 (62.0)      | 378 (58.9)    | 94 (79.0) | <0.0005 |
| Fatigue             | 372 (48.9)      | 312 (48.6)    | 7 (5.9)   | 0.41 |
| Altered mental status | 54 (7.1)   | 53 (7.6)      | 1 (0.8)   | 0.004 |
| Headaches           | 54 (7.1)        | 53 (7.6)      | 1 (0.8)   | 0.004 |
| Loss of taste       | 53 (7.0)        | 49 (7.6)      | 6 (5.0)   | 0.08 |
| Loss of smell       | 53 (7.0)        | 49 (7.6)      | 6 (5.0)   | 0.08 |
| Congestion          | 23 (3.0)        | 22 (3.4)      | 1 (0.8)   | 0.24 |
| Fatigue             | 372 (48.9)      | 312 (48.6)    | 7 (5.9)   | 0.41 |
| Altered mental status | 54 (7.1)   | 53 (7.6)      | 1 (0.8)   | 0.004 |
| Headaches           | 54 (7.1)        | 53 (7.6)      | 1 (0.8)   | 0.004 |
| Loss of taste       | 53 (7.0)        | 49 (7.6)      | 6 (5.0)   | 0.08 |
| Loss of smell       | 53 (7.0)        | 49 (7.6)      | 6 (5.0)   | 0.08 |
| Congestion          | 23 (3.0)        | 22 (3.4)      | 1 (0.8)   | 0.24 |
| Fatigue             | 372 (48.9)      | 312 (48.6)    | 7 (5.9)   | 0.41 |
| Altered mental status | 54 (7.1)   | 53 (7.6)      | 1 (0.8)   | 0.004 |
| Headaches           | 54 (7.1)        | 53 (7.6)      | 1 (0.8)   | 0.004 |
| Loss of taste       | 53 (7.0)        | 49 (7.6)      | 6 (5.0)   | 0.08 |
| Loss of smell       | 53 (7.0)        | 49 (7.6)      | 6 (5.0)   | 0.08 |
| Congestion          | 23 (3.0)        | 22 (3.4)      | 1 (0.8)   | 0.24 |

Table 3

Oxygen therapy required by the COVID-19 patients during their hospital stay.

| Oxygen therapy required | Total Survivors | Non survivors | P value |
|-------------------------|-----------------|---------------|---------|
|                         | N = 761         | N = 642       | N = 119 |
|                         | Mean ± SD       | Mean ± SD     | Mean ± SD |
|                         | N (%)           | N (%)         | N (%)   |
| Noninvasive ventilation within the first 24 h | 307 (40.3) | 213 (31.2) | 94 (79.0) | <0.0005 |
| Noninvasive ventilation within 24–48 h | 295 (38.8) | 208 (32.4) | 87 (73.1) | <0.0005 |
| Intubation within the first 24 h | 24 (3.2) | 11 (1.7) | 13 (10.9) | <0.0005 |
| Intubation within 24–48 h | 26 (3.4) | 6 (0.9) | 20 (16.8) | <0.0005 |
| Mechanical ventilation anytime throughout the hospital stay | 106 (13.9) | 21 (3.3) | 85 (71.4) | <0.0005 |
among adults younger than 65 years (31). This is most likely multifac- torial and could be due to the impairment of immune function in obese patients (32-35). The above studies are in line with the results of this study where age and obesity were found to be independent risk factors of mortality in COVID-19.

Liu et al. reported an 8% increase in in-hospital mortality for each unit increase in NLR (OR = 1.08; 95% CI = [1.01 to 1.14], \( p = 0.0147 \)) (36). A meta-analysis by Li et al. demonstrated an association between NLR and mortality with a pooled sensitivity of 0.83 (95% CI [0.75–0.89]), a pooled specificity of 0.83 (95% CI [0.74–0.89]) and a

### Table 4
Outcomes of patients with COVID-19.

| Test Result Variable(s) | AUC | Asymptotic 95% Confidence Interval | P-value |
|-------------------------|-----|-----------------------------------|---------|
|                         |     | Lower Bound                       | Upper Bound | |
| Lactate                 | 0.53| 0.42                              | 0.65      | 0.56 |
| Neutrophil lymphocyte ratio | 0.64| 0.53                              | 0.75      | 0.02 |
| Procalcitonin           | 0.60| 0.48                              | 0.71      | 0.10 |
| D-Dimer                 | 0.67| 0.57                              | 0.77      | 0.003 |
| Pro-BNP                 | 0.65| 0.55                              | 0.76      | 0.009 |
| Ferritin                | 0.59| 0.47                              | 0.70      | 0.13 |
| Troponin                | 0.64| 0.53                              | 0.75      | 0.02 |
| CT severity score       | 0.66| 0.55                              | 0.77      | 0.005 |
| Lactate dehydrogenase   | 0.66| 0.55                              | 0.77      | 0.007 |
| CRP                     | 0.60| 0.49                              | 0.71      | 0.08 |

**Fig. 3.** ROC curves for the different biomarkers with the primary outcome being in-hospital mortality among COVID-19 patients (with their respective AUCs).
predicting 30-day mortality, and a score reported that a CT severity score (≥90; p = 0.005 and an OR of 1.17). In addition, interrater reliability was not tested since each medical chart was reviewed by a single data abstractor and each CT image and CT severity score were reviewed by a single radiologist. All the included patients were not vaccinated as the vaccine was not available at the time. Vaccine status might have an influence on biomarker levels, CT findings and hospital outcomes. Also, the study was conducted before the emergence and testing of the different COVID-19 variants. Despite the previous limitations, a large proportion of the world population remains unvaccinated. In addition, in the setting of the emergence of new COVID-19 variants breakthrough cases still occur in fully vaccinated patients. Thus, our results remain relevant to date. Moreover, we only included patients with a positive RT-PCR. We are well aware of the false negative rate of the PCR and that some patients would have had the clinical and radiographic presentations COVID during the study period and were not included. However, we are not sure of the number of those patients.

We did not trend biomarker levels and did not obtain a second semi-quantitative CT score. This could have provided further information on their prognostic utility. The next step would be to conduct a prospective multi-center study to validate our results.

### 4.1. Limitations

Our study has several limitations. It was a retrospective single-center study which can limit the generalizability of the results and lead to selection bias. The study only included COVID-19 patients who underwent a CT chest. This would lead to a selection bias of sicker COVID-19 patients since a CT chest would be more likely ordered for this patient population. A CT chest would not be ordered for COVID-19 patients with a milder presentation. The individuals involved in data abstraction were not blinded to the hypothesis and outcomes of the study since they were involved in the writing of the manuscript (however they were not involved in the analysis of the data). In addition, interrater reliability was not tested since each medical chart was reviewed by a single data abstractor and each CT image and CT severity score were reviewed by a single radiologist. All the included patients were not vaccinated as the vaccine was not available at the time. Vaccine status might have an influence on biomarker levels, CT findings and hospital outcomes. Also, the study was conducted before the emergence and testing of the different COVID-19 variants. Despite the previous limitations, a large proportion of the world population remains unvaccinated. In addition, in the setting of the emergence of new COVID-19 variants breakthrough cases still occur in fully vaccinated patients. Thus, our results remain relevant to date. Moreover, we only included patients with a positive RT-PCR. We are well aware of the false negative rate of the PCR and that some patients would have had the clinical and radiographic presentations COVID during the study period and were not included. However, we are not sure of the number of those patients.

We did not trend biomarker levels and did not obtain a second semi-quantitative CT score. This could have provided further information on their prognostic utility. The next step would be to conduct a prospective multi-center study to validate our results.

### Ethics approval and consent to participate

The design of this study ensured that it strongly abided by all ethical considerations according to the hospital’s Institutional Review Board (IRB), and consent for participation was waived as this was a retrospective chart review. Reference number: BIO-2020-0548.

### Consent for publication

Not applicable.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Funding

None.

### CRediT authorship contribution statement

**Gilbert Abou Dagher:** Writing – review & editing, Writing – original draft, Supervision, Data curation, Conceptualization. **Alain Abi Ghanem:** Writing – review & editing, Writing – original draft, Supervision, Data curation, Conceptualization. **Saadeddine Haidar:** Writing – review & editing, Writing – original draft, Data curation, Conceptualization. **Nadim Kattouf:** Writing – review & editing, Writing – original draft, Data curation, Conceptualization. **Mohamad Assaf:** Writing – review & editing, Writing – original draft, Data curation, Conceptualization. **Mihran Khdir:** Writing – review & editing, Writing – original draft, Data curation, Conceptualization. **Reve Chahine:** Writing – review &

---

**Table 5**

Stepwise logistic regression with the primary outcome being in-hospital mortality.

| OR       | 95% CI       | P-value |
|----------|--------------|---------|
| Age      | 1.07         | 1.05    | 1.09 | <0.0001 |
| Obesity  | 2.02         | 1.25    | 3.26 | 0.004   |
| Neutrophil/lymphocyte ratio | 1.02   | 1.01 | 1.04 | 0.003 |
| CRP      | 1.01         | 1.004   | 1.01 | <0.0001 |
| Lactate dehydrogenase | 1.003 | 1.001 | 1.004 | <0.0001 |
| CT severity score | 1.17 | 1.12 | 1.23 | 0.0001 |

Variables included in the model: Age, gender (reference: female); BMI; smoking (reference: none); obesity (reference: no); Hypertension; Dyslipidemia; Artrial fibrillation; Coronary Artery Disease; Congestive Heart Failure; Malignancy; Diabetes Mellitus; Chronic Obstructive Pulmonary Disease; Neutrophil/lymphocyte ratio; Troponin; CRP; Procalcitonin (ng/mL); Lactate dehydrogenase; Ferritin; D-dimer; IL-6; Pro-BNP; CT severity score.

---

**Data curation, Conceptualization.**
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements
None.

References

[1] World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed October 20, 2020.

[2] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.

[3] Wu C, Chen X, Xiao Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1–11.

[4] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. http://dx.doi.org/10.1016/S0140-6736(20)30183-5. Published: 3198264.

[5] Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of radiol.2020201433. Epub 2020 Apr 17. PMID: 32301647; PMCID: PMC7233395.

[6] Liu Fengjun Zhang, Huang Qi, Wang Chao, Shi Lin, Fang Nannan, Shan Cong, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10:5613–22. https://doi.org/10.7150/thno.49585.

[7] Pascale Marco Lafata, Giovanni Franco, Coco Giorgio Maria, Cilia Simona, Manganaro Francesca, Panchebano Lucia, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30:https://doi.org/10.1007/s00330-020-07033-y.

[8] Rostami Mehrdad, Mansouritorghabeh Hassan. D-dimer level in COVID-19 infection: a systematic review and its relationship with clinical features for assessing the severity of patients with COVID-19. Korean J Radiol. 2020;21:https://doi.org/10.3344/kjr.2020.22931.

[9] Ruiz Martinian Zhang, Huang Qi, Wang Chao, Shi Lin, Fang Nannan, Shan Cong, et al. Cardiac troponin I in patients infected with SARS-CoV-2: a systematic review. Allergy. 2021;76:428–35. https://doi.org/10.1111/all.14657.

[10] Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020 Jul;92(7):856–62. https://doi.org/10.1002/jmv.25871. Epub 2020 Apr 25. PMID: 32281362; PMCID: PMC7195072.

[11] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1–11. https://doi.org/10.1002/jim.13119.

[12] Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020 Jun–Jul;62:265–72. https://doi.org/10.1016/j.pcad.2020.05.003. Epub 2020 May 14. PMID: 32348466.

[13] Liu Fengjun Zhang, Huang Qi, Wang Chao, Shi Lin, Fang Nannan, Shan Cong, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10:5613–22. https://doi.org/10.7150/thno.49585.

[14] Pascale Marco Lafata, Giovanni Franco, Coco Giorgio Maria, Cilia Simona, Manganaro Francesca, Panchebano Lucia, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30:https://doi.org/10.1007/s00330-020-07033-y.

[15] Liu Fengjun Zhang, Huang Qi, Wang Chao, Shi Lin, Fang Nannan, Shan Cong, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10:5613–22. https://doi.org/10.7150/thno.49585.

[16] Pascale Marco Lafata, Giovanni Franco, Coco Giorgio Maria, Cilia Simona, Manganaro Francesca, Panchebano Lucia, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30:https://doi.org/10.1007/s00330-020-07033-y.

[17] Rostami Mehrdad, Mansouritorghabeh Hassan. D-dimer level in COVID-19 infection: a systematic review and its relationship with clinical features for assessing the severity of patients with COVID-19. Korean J Radiol. 2020;21:https://doi.org/10.3344/kjr.2020.22931.

[18] Ruiz Martinian Zhang, Huang Qi, Wang Chao, Shi Lin, Fang Nannan, Shan Cong, et al. Cardiac troponin I in patients infected with SARS-CoV-2: a systematic review. Allergy. 2021;76:428–35. https://doi.org/10.1111/all.14657.

[19] Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020 Jul;92(7):856–62. https://doi.org/10.1002/jmv.25871. Epub 2020 Apr 25. PMID: 32281362; PMCID: PMC7232341.

[20] Liu Fengjun Zhang, Huang Qi, Wang Chao, Shi Lin, Fang Nannan, Shan Cong, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10:5613–22. https://doi.org/10.7150/thno.49585.

[21] Pascale Marco Lafata, Giovanni Franco, Coco Giorgio Maria, Cilia Simona, Manganaro Francesca, Panchebano Lucia, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30:https://doi.org/10.1007/s00330-020-07033-y.

[22] Liu Fengjun Zhang, Huang Qi, Wang Chao, Shi Lin, Fang Nannan, Shan Cong, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10:5613–22. https://doi.org/10.7150/thno.49585.

[23] Pascale Marco Lafata, Giovanni Franco, Coco Giorgio Maria, Cilia Simona, Manganaro Francesca, Panchebano Lucia, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30:https://doi.org/10.1007/s00330-020-07033-y.

[24] Rostami Mehrdad, Mansouritorghabeh Hassan. D-dimer level in COVID-19 infection: a systematic review and its relationship with clinical features for assessing the severity of patients with COVID-19. Korean J Radiol. 2020;21:https://doi.org/10.3344/kjr.2020.22931.

[25] Pascale Marco Lafata, Giovanni Franco, Coco Giorgio Maria, Cilia Simona, Manganaro Francesca, Panchebano Lucia, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30:https://doi.org/10.1007/s00330-020-07033-y.
E-Nicholson CJ, Wooster L, Sigurslid HH, Li RH, Jiang W, Tian W, et al. Estimating risk of mechanical ventilation and in-hospital mortality among adult COVID-19 patients admitted to mass general Brigham: the VICE and DICE scores. EclinicalMedicine. 2021 Mar 1;133:100765.

Herold T, Jurinovic V, Arnaech C, Lipworth BJJ, Hellmuth JC, von Bergwelt-Baldon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020 Jul 1;146(1):128–36.

Acar E, Demir A, Yıldırım B, Kaya MG, Göçek K. The role of hemogram parameters and C-reactive protein in predicting mortality in COVID-19 infection. Int J Clin Pract. 2021 Jul;75(7):e14256. https://doi.org/10.1111/ijcp.14256. Epub 2021 Apr 30. PMID: 33887100; PMCID: PMC8250321.

Lentner Jacob, Adams Taylor, Knutson Valene, Zeien Sarah, Abbas Hassan, Moosavi Ryan, et al. C-reactive protein levels associated with COVID-19 outcomes in the United States. J Osteopath Med. 2021;121(12):869–73. https://doi.org/10.1515/jom-2021-0103.

Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase. [Updated 2021 May 7]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan Available from: https://www.ncbi.nlm.nih.gov/books/NBK557536/.

Yan L, Zhang HT, Gonçalves J, Xiao Y, Wang M, Guo Y, et al. An interpretable mortality prediction model for COVID-19 patients. Nature Machine Intelligence. 2020 May;2(5):283–8.

Drent M, Cobben NA, Henderson BF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996 Aug;9(8):1736–42.

Zhang JJ, Lee KS, Ang LW, Leo YS, Young BE. Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis, and meta-regression analysis. Clin Infect Dis. 2020 Oct 15;71(16):2199–206.

Colombi D, Bodini FC, Petrini M, Maffi G, Morelli N, Milanesi G, et al. Well- aerated Lung on admitting chest CT to predict adverse outcome in COVID-19 Pneumonia. Radiology. 2020 Aug;296(2):886–96. https://doi.org/10.1148/radiol.2020201433. Epub 2020 Apr 17. PMID: 32301647; PMCID: PMC7233411.

Yu Q, Wang Y, Huang S, Liu S, Zhou Z, Zhang S, et al. Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients. Theranostics. 2020 Apr 27;10(12):5641–8. https://doi.org/10.7150/thno.46465. PMID: 32372337; PMCID: PMC7196305.

Zhang JJ, Cao YY, Tan G, Dong X, Wang BC, Lin J, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy. 2021 Feb;76(2):533–50. https://doi.org/10.1111/all.14496. Epub 2020 Aug 24. PMID: 32662525; PMCID: PMC7404752.

Løevld AW, Azijli K, Truusinen BP, van Haafken RM, Kootte RS, van den Berk IA, et al. Chest CT in COVID-19 at the ED: validation of the COVID-19 reporting and data system (CO-RADS) and CT severity score: a prospective, multicenter, observational study. Chest. 2021 Mar 1;159(1):1126–35.